Loading...

IBRX IMMUNITYBIO INC US FDA Inspections 8-K Filing

MMNT

BRX

IMMUNITYBIO INC

(IBRX)

2026 8-K

Financial Results Update

Financial Results Update

FDA Response Update

Revenue Agreement Update

Financial Results Update

Regulatory Approval

Convertible Note Amendment

Financial Results Update

Regulatory Approval

Stock Issuance Update

Board Appointment

Regulatory Update

Financial Update

Equity Offerings

Management Changes

Financial Statements

Regulatory Compliance

Financial Update

Executive Compensation

Director Resignation

Public Offering

Study Data Release

Annual Meeting of Stockholders

Quantitative Data

Bonuses and Incentive Awards

Quantitative Data in Filing

Quantitative Data

Financial Agreement and Ann...

Other Special Situation

Quantitative Data

Quantitative Data

Stock Purchase Agreement

Financial Update

Quantitative Data

External Links:

On April 6, 2026, ImmunityBio, Inc. announced that it submitted a comprehensive response to a Warning Letter from the FDA regarding prescription drug promotion issued on March 13, 2026, detailing its corrective actions.

AI Assistant

IMMUNITYBIO INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.